Apr 27, 2023 4:30pm EDT Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer
Apr 18, 2023 1:30pm EDT Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023
Mar 30, 2023 4:30pm EDT Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
Mar 17, 2023 4:01pm EDT Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 17, 2023 4:01pm EST Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 09, 2023 4:05pm EST Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
Jan 04, 2023 8:00am EST Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference